Fc. Tenover et al., Detection and reporting of organisms producing extended-spectrum beta-lactamases: Survey of laboratories in Connecticut, J CLIN MICR, 37(12), 1999, pp. 4065-4070
Extended-spectrum beta-lactamases (ESBLs) are enzymes produced in some gram
-negative bacilli that mediate resistance to extended-spectrum cephalospori
ns and aztreonam. They are most common in Klebsiella spp. and Escherichia c
oli but are present in a variety of Enterobacteriaceae. Resistance mediated
by these enzymes can be difficult to detect depending on the antimicrobial
agents tested. AmpC beta-lactamases are related to the chromosomal enzymes
of Enterobacter and Citrobacter spp, and also mediate resistance to extend
ed-spectrum cephalosporins and aztreonam in addition to cephamycins, such a
s cefoxitin. Unlike ESBLs, however, AmpC beta-lactamases are not inhibited
by clavulanic acid or other similar compounds. To assess the abilities of v
arious antimicrobial susceptibility testing methods to detect ESBLs, we sen
t three ESBL-producing organisms, one AmpC-producing organism, and a contro
l strain that was susceptible to extended-spectrum cephalosporins to 38 lab
oratories in Connecticut for testing. Eight (21.0%) of 38 Labs failed to de
tect extended-spectrum cephalosporin or aztreonam resistance in any of the
ESBL- or AmpC-producing isolates. Errors were encountered with both automat
ed and disk diffusion methods. Conversely, seven (18.4%) labs categorized a
t least some of the four resistant isolates as potential ESBL producers and
reported the results with the extended-spectrum cephalosporins and aztreon
am as resistant as suggested by current National Committee for Clinical Lab
oratory Standards (NCCLS) guidelines. The percentage of laboratories that f
ailed to detect resistance in the ESBL or AmpC isolates ranged from 23.7 to
31.6% depending on the type of enzyme present in the test organism, This s
urvey suggests that many laboratories have difficulty detecting resistance
in ESBL and AmpC-producing organisms and may be unaware of the NCCLS guidel
ines on modifying susceptibility testing reports for ESBL-producing strains
.